In this small prospective study, 15 patients with unresectable, locoregionally advanced cutaneous squamous cell carcinoma were treated with 70 Gy in 35 fractions, concurrent chemo, and concurrent durvalumab. The complete response rate was 60%, and progression free survival at 24 months was 65%. | Lin, Adv Radiat Oncol 2026
